To determine whether repeat administration of an adenovector (Ad) into the eye results in efficient gene delivery and to test whether transgenes can be expressed from an adenovector expression system in the presence of preexisting, neutralizing anti-Ad antibodies.
A ge-related macular degeneration (AMD), a deterioration of the central portion of the retina, is the chief cause of severe and irreversible vision loss in aging populations.
1 AMD can be categorized into an atrophic (dry) form and a neovascular (wet, exudative) form. The atrophic form involves alterations of pigment distribution, loss of retinal pigment epithelial (RPE) cells and photoreceptors, and diminished retinal function due to an overall atrophy of the cells. The neovascular AMD involves proliferation of abnormal choroidal vessels, which penetrate the Bruch's membrane and RPE layer into the subretinal space, and thereby may form extensive clots and/or scars. This eventually leads to the formation of choroidal neovascular (CNV) membranes, from which blood and serum may leak. 2 The fluid released from the CNV can damage the structure and function of the overlying retina, including the central macular area, leading to the loss of central vision. The exact cause of CNV is not clear; however, it is often associated with a buildup of abnormal extracellular deposits in the form of soft drusen between the aging RPE and Bruch's membrane, resulting in localized areas of ischemia and triggering angiogenesis. 3 Adenovectors are a useful protein expression system for the treatment of ocular diseases, such as AMD. 4 They efficiently transduce a variety of ocular cells after intravitreal (IVT) 5 and periocular (PO) 6 administration; however, transgene expression is transient and is known to decrease from initial levels. 5, 7, 8 In the case of IVT delivery, cells specifically transduced are cells of the iris, ciliary body, trabecular meshwork, and corneal endothelium. 5 After PO delivery, cells transduced include the sclera, episclera, and surrounding orbital connective tissue. 6 Important aspects of successful adenovirus gene transfer or therapeutic purposes include the amount and persistence of gene expression, the ability to readminister vector, and the localization of vector-directed gene expression to target organs. 9 Because repeat administration of adenovector may then be necessary to maintain therapeutic expression, we undertook a series of studies to determine whether repeat administration of an adenovector in the eye is feasible, and to evaluate transgene expression after single and multiple IVT or PO injections. In other tissues, it has been suggested that immunologic limitation to prolonged transgene expression is the development of adenovector-specific neutralizing antibodies after primary administration, which may hinder repeat administration of adenovector. 10, 11 Because the eye is an immune privileged organ, we also tested whether preexisting neutralizing anti-Ad antibodies would block transgene expression in the eye by inducing anti-Ad antibodies with single and multiple intramuscular (IM) injections of AdNull.11D.
MATERIALS AND METHODS

Animals
Female, C57Bl/6 mice were obtained from Harlan Laboratories (Chicago, IL) at 6 to 8 weeks of age. Before treatment, mice were anesthetized with a 100-L intraperitoneal injection of ketamine hydrochloride (40-mg/kg) and xylazine (12- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 
Adenoviral Vector Expressing Luciferase
Production and quantification of a type-5 adenoviral vector that expresses luciferase from a cytomegalovirus (CMV) immediate early promoter expression cassette has been described. 12 The vector (AdL.11D) is devoid of the E1A, E1B, E3, and E4 adenovirus replication regions. A similar vector lacking an expression cassette (AdNull.11D) was also used.
Adenoviral Vector Injections
IVT injections of vectors were performed using a pump microinjection apparatus (Harvard Apparatus, Holliston, MA) and pulled-glass micropipettes, as previously described. 13 Each micropipette was calibrated to deliver approximately 2 L of vehicle containing the appropriate number of viral particles, on depression of a foot switch. The mice were anesthetized, pupils were dilated, and under a dissecting microscope (Nikon, Melville, NY), the sharpened tip of the micropipette was passed through the sclera, just behind the limbus into the vitreous cavity, and the foot switch was depressed. Depression of the foot switch caused a jet injection of fluid to penetrate the vitreous space.
Periocular injections were performed with a cannula-syringe system, a 100-L glass syringe (Hamilton Co., Reno, NV) fitted with a 33-gauge cannula, placed into a syringe pump (Harvard Apparatus). The mice were anesthetized as previously described. Under a stereofluorescence microscope with automated focus capabilities (Leica Microsystems, Deerfield, IL), the cannula was inserted under the conjunctiva. A foot pedal was depressed to signal the syringe pump to inject 4 L of vehicle containing the appropriate number of viral particles.
Intramuscular injections of vector were delivered in a total volume of 100 L and administered in three equal injections to the right hind limb.
Assessment of Luciferase Expression
Immediately after enucleation, eyes were snap frozen and stored at Ϫ80°C. Eyes were ground with a cold mortar and pestle on dry ice and then lysed (Reporter Lysis Buffer; Promega, Madison, WI). Lysates were analyzed with a luciferase assay system according to the manufacturer's protocol. The total protein concentration was determined, to normalize the measurement of luciferase expression based on a Bradford dye-binding procedure with a protein assay (Bio-Rad Laboratories, Hercules, CA).
Neutralizing Anti-Ad Antibody Assay
Neutralizing antibody titers were determined as previously described. 7 Titers were determined by analyzing the ability of serum antibody to inhibit infection of an Ad-green fluorescent protein (GFP; E1-, E3-deleted) serotype 5 adenovector expressing GFP from the CMV promoter) on AE25 cells, which complement for E1 functions and support the growth of E1-deleted adenovectors. AE25 cells were inoculated at 1 ϫ 10 4 per well on flat-bottomed 96-well plates and grown for 18 to 24 hours at 37°C. A series of two-or fourfold dilutions of the serum samples were incubated with AdGFP at a multiplicity of infection of 5 focal-forming units per cell for 1 hour at 37°C in minimal DMEM. This mixture was incubated with AE25 cells for 1 hour at 37°C, 100 L of complete medium was added, and the cells were cultured overnight. The percentage of infected cells was determined with an imaging system (Typhoon 9200; GE Healthcare, Sunnyvale, CA), and confirmed with a fluorescence microscope (Nikon). The neutralizing antibody titer was scored as the reciprocal of the last dilution where a 50% reduction in green cells (infected cells) was observed. Because the neutralizing antibody is directed at the exterior protein coat of the adenovector, this assay is applicable to all serotype 5 adenovectors, independent of whether the vector is E1-and E3-deleted or E1-, E3-, and E4-deleted. All samples were assayed in duplicate.
Statistical Analysis
Results are expressed as the mean Ϯ SEM. An overall test for treatment effect was first performed with one-way analysis of variance (ANOVA). If the overall test indicated a significant treatment effect, individual treatments were compared with the naïve treatment group, using Bonferroni analyses, which adjusted for multiple comparisons. The level established for statistical significance was P Ͻ 0.05 (two-tailed test). All analyses were performed on computer (Origin 7.5; Origin Laboratories, Northampton, MA).
RESULTS
High-Level Gene Expression after Repeated Ocular Doses with the Adenovector
To assess repeated doses of the eye with an adenovector, we used a scheme that exposed mice to a vector without a marker gene (AdNull.11D) and then measured efficiency of delivery using the marker gene luciferase in AdL.11D. Mice were given IVT or PO AdNull.11D (1 ϫ 10 9 pu) one, two, or three times at 2-week intervals. Twenty-four hours before death, mice were given a single IVT or PO injection of AdL.11D (1 ϫ 10 9 pu), and luciferase activity was determined. Naïve mice served as the negative (no injection) control; whereas, mice that received a single IVT or PO injection of AdL.11D (1 ϫ 10 9 pu) served as the positive control, because there are no prior interfering immune responses that might suppress marker (luciferase) gene expression. The experimental design is shown in Figure  1 . We found that single or repeated IVT or PO injections with adenovector (AdNull.11D) did not ablate luciferase expression after one, two, and up to three prior adenovector administrations (Fig. 2) . Although luciferase expression declined modestly after IVT delivery, luciferase activity remained approximately 1000-fold above the noninjected control, even after four closely spaced IVT (Fig. 2A) or PO (Fig. 2B) administrations. This result was surprising, because repeated administration in other tissues (i.e., liver, lung, and pancreas) at 2 weeks after administration of adenovectors leads to ablated responses attributable to increasing titers of circulating neutralizing ad- There is a statistically significant difference between results in the treatment and naïve groups (P Ͻ 0.05, one-way ANOVA). Furthermore, difference in the results between the treatment groups (except for the AdL only control, P ϭ 0.08 and 0.26; IVT and PO, respectively) and the naïve group is greater than would be expected by chance.
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enovector antibodies. 8,10,14 -18 Of interest, repeated PO administration resulted in minimal decreases in gene expression, even less than repeated IVT administration. This was somewhat surprising, as it was anticipated that the periocular space would be a more systemically exposed space than the intraocular space. Also, of interest is that the expression profile after a second administration (e.g., IVT) mimicked the initial administration with respect to maximum transgene levels and expression duration (McVey D, et al., manuscript in preparation). Thus, these data demonstrate that repeated IVT or PO adenovector delivery to the eye (up to four times) does not ablate transgene expression, but rather gene expression is still possible.
Neutralizing Anti-Ad Antibody Activity after Repeated Doses to the Eye
To assess whether IVT or PO injections of adenovector induce neutralizing antibodies, we collected serum from the same animals after single or multiple injections of AdNull.11D in a delivery scheme similar to that described for experiments measuring gene delivery (Fig 2) . One, two, and three repeat IVT or PO injections of adenovector stimulated neutralizing anti-Ad antibody serum titers (Fig. 3A, 3B, respectively) . This indicates that the gene delivery shown in Figure 2 occurred even when an immune response to the vector existed. These data then indicate the feasibility of repeated IVT or PO administration, even in the presence of circulating neutralizing adenovector antibody titers. That robust neutralizing (Ͼ1:10,000) anti-Ad antibody titers were not generated after single or repeated ocular administrations of vector (up to four times) confirms that the eye is immune-privileged. Titers of neutralizing anti-Ad antibody did not increase immediately, but gradually increased (with subsequent IVT or PO administrations). Furthermore, four IVT or PO administrations were necessary to achieve the same level of neutralizing anti-Ad antibody response observed after a single IM injection of AdNull.11D (1 ϫ 10 9 pu).
Gene Expression in Preimmunized Animals after Ocular Administration
To further substantiate whether transgene expression in the eye is possible in the presence of preexisting circulating neutralizing anti-Ad antibodies, we purposely induced a systemic immune response by using repeated IM injections of AdNull.11D. The experimental design is shown in Figure 4 . Mice were injected with AdNull.11D (1 ϫ 10 9 pu) intramuscularly (one, two, or three times) at 2-week intervals. AdNull.11D (1 ϫ 10 10 pu) resulted in similar levels of neutralizing antibodies (data not shown). To measure gene transfer in the eyes, approximately 24 hours before death, mice received a single IVT or PO injection of AdL.11D (1 ϫ 10 9 pu). Naïve mice were used as the negative control, and mice receiving a single IVT or PO injection of AdL.11D (1 ϫ 10 9 pu) without preimmunization were used as the positive control for maximum gene expression. Results shown in Figure 5 indicate that transgene expression after IVT or PO administration occurred, even in the presence of circulating anti-Ad antibody titers. Although gene expression declined after IVT delivery, as evident by reduction in luciferase expression, gene transfer and expression clearly was able to continue within the eye, despite previous systemic exposure of the animal to adenovector and in the presence of elevated neutralizing adenovector antibody titers compared with naïve animals (discussed later). Luciferase activity remained approximately 100-to 1000-fold above the noninjected control after three preimmunization IM injections in both the IVT (Fig. 5A) and PO (Fig. 5B) groups.
Neutralizing Anti-Ad Antibody Activity in Preimmunized Animals
To confirm whether single or multiple IM injections would result in increased neutralizing anti-Ad antibodies, levels were measured in serum samples processed from whole blood collected at the time the animals were killed (Fig. 6) . We selected . 19 Adenovectors are of interest to ocular applications, because they have been shown to transduce both the anterior and posterior segments of the eye, 5 and their efficiency in gene transfer is high. 20 However, gene expression with adenovectors typically are reported to be transient. Repeated administration of adenovector may be desirable for some disease indications to obtain optimal therapeutic benefit. 21 Results in this article indicate that repeat IVT or PO administration of adenovector to the eye can result in repeated transgene expression, even when circulating immune responses to the vector are induced or are elevated compared with nontreated animals.
Previous studies have indicated that in the practice of gene delivery, readministration of adenovectors may not result in additional gene transfer, particularly after intravenous, intraperitoneal, or intratracheal administration. 11, 17, 21 However, because the eye is an immune-privileged organ, we reasoned that IVT administration to the eye might respond differently. An IVT introduction of adenovectors may lead to a different induction profile of neutralizing anti-Ad antibodies than in other organs injected with adenovectors. 11, 18 ,21 Thus, we tested the efficacy of gene transfer and expression after repeated IVT or PO adenovector administration to the eye and determined the neutralizing anti-Ad antibody titers. There is a statistically significant difference between results in the treatment and naïve groups (P Ͻ 0.05, one-way ANOVA). Furthermore, differences in the results in the treatment groups (except for the AdL only control, P ϭ 0.08 and 0.21; IVT and PO, respectively) compared with the naïve is greater than would be expected by chance.
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Our results are consistent with the concept that the eye is immune privileged, in that ocular injections produced a weak systemic immune response. Intraocularly, IVT delivery of adenovectors (E1, E3, and E4-deleted) can lead to nonsuppurative inflammation within the eye, but this effect is dose dependent. At the same dose, 1 ϫ 10 9 pu, as used in this study, the inflammation was minimal with some lymphocytes, a few plasma cells, occasional macrophages, and rare neutrophils and eosinophils. 22 Repeated IVT or PO administration of adenovector in the eye, even up to four times, at a brisk interval (2-weeks) was necessary, to induce circulating neutralizing antibodies equivalent to a single IM injection. Gene delivery experiments in the other systems indicate the rapid induction of multiple immune responses against viral and transgene proteins of adenovectors, including neutralizing antibodies and cytotoxic T lymphocyte (CTL) responses. 23 B-cell activation and a humoral immune response are widely implicated in the inhibition of successful readministration of adenovectors for nonocular tissues. 9, 10 After the initial exposure to adenovectors, neutralizing antibodies (IgG and IgA) are generated against major viral capsid proteins, which can attenuate infection of cells, even after the second administration in the heart and lung tissues. 9, 10 The immune-privileged nature of the eye was also noted after subretinal injection, where minimal anti-Ad antibody production, and successful repeated doses were observed. 24 Most interesting, we found that repeat periocular administrations induced very low neutralizing antiadenovector titers. These results suggest that the periocular space may be immune privileged as well.
Preimmunization of the animals before ocular injection of adenovectors indicated that the presence of an immune response has little impact on the efficiency of adenovector expression. Preimmunization of mice through intramuscular delivery, produced little change in adenovector delivery both intravitreally and periocularly. This indicates that elevated serum levels of neutralizing anti-Ad antibody levels do not necessarily ablate gene expression from adenovectors introduced into the eye. Our findings have several clinical implications. First, the presence of neutralizing anti-Ad antibody titers in the serum of patients does not necessarily correlate with transgene expression. Approximately 30% to 70% of the United States population has preexisting neutralizing anti-Ad antibody titers, 25 ,26 yet to date a tight correlation between serum levels of anti-Ad antibodies and any clinical parameter has not been shown. This is of particular interest, as previous clinical trials in other tissues indicate that humans with neutralizing anti-Ad antibody levels may respond to adenovector mediated gene delivery systems. [27] [28] [29] A second clinical implication of this article is to support the concept that repeated adenovector administration (IVT or PO) is feasible. Our results are consistent with an ongoing repeated dose trial with a first-generation adenovector (lacking E1 and E3) in children with retinoblastoma (Chevez-Barrios P, et al. IOVS 2004;45:ARVO E-Abstract 3360). To date, results from this trial indicate that repeated administration to the eye (Ն1 e10 pu per injection) is well tolerated and does not induce or boost systemic immune responses to adenovirus and that patients show a clinical response to this experimental therapy (Chevez-Barrios P, et al. IOVS 2005;46:ARVO E-Abstract 5218). Taken together, these data indicate that repeated administration of adenovectors to the eye in patients can be considered an option for future clinical trial designs.
